Vice President, U.S. Market Access & Pricing

The Vice President, Market Access will lead the strategy and execution of all market access activities to support the successful launch of the company’s adult pneumococcal vaccine. Reporting to the Chief Commercial Officer, this role will be accountable for ensuring broad, timely, and sustainable access across public and private channels.

As Vaxcyte prepares for its first commercial launch, the VP will operate as a hands-on leader, building foundational capabilities while directly shaping payer, provider, and policy environments. This role requires a balance of strategic leadership and execution, with a particular focus on navigating the unique access dynamics of adult vaccines, including public health recommendations, buy-and-bill reimbursement, and site-of-care considerations.

• Lead development and execution of the U.S. market access strategy for the adult pneumococcal vaccine, including pricing, reimbursement, contracting, and channel strategy
• Define and drive launch readiness plans aligned to regulatory approval and immunization guideline milestones (e.g., ACIP or other recommending bodies)
• Shape access strategies across commercial payers, Medicare, Medicaid, and public health channels
• Develop and execute engagement strategies for key stakeholders, including GPOs, IDNs, retail pharmacy, and public health entities
• Establish pricing strategy and gross-to-net assumptions, ensuring alignment with vaccine-specific market dynamics
• Ensure readiness for coding, coverage, reimbursement, and provider economics within buy-and-bill and pharmacy settings
• Partner with Medical Affairs to define and deliver HEOR and value evidence to support payer and policy decision-making
• Serve as the market access lead across cross-functional teams, aligning with Commercial, Medical, Regulatory, Government Affairs, and Finance
• Build and lead a lean market access function, leveraging external partners to scale capabilities efficiently
• Working cross functionally, prepare for CDC immunization program, state immunization program, and ACIP-adjacent policy stakeholder engagements; translate ACIP recommendation language into access and coverage implications across all channels
• Develop and execute integrated PBM, commercial payer, and Medicare Part B and D contracting strategies to ensure optimal formulary positioning, coverage, and patient access across channels.
• Support development of national retail pharmacy and alternate vaccination site strategies, establishing partnerships that maximize vaccine availability, administration, and uptake.
• Develop scenario-based access, reimbursement, and customer adoption strategies aligned to potential ACIP recommendation outcomes and evolving adult immunization guidelines

• Bachelor’s degree required; advanced degree (MBA, MPH, PharmD, PhD) preferred
• 15+ years of experience in market access, pricing, reimbursement, or related functions within biotech/pharma
• Demonstrated experience supporting or leading product launches, ideally in vaccines, infectious disease, or buy-and-bill products
• Strong understanding of adult vaccine access dynamics, including public health recommendations, Medicare Part B and Part D reimbursement, Medicaid, 340B program implications, CDC contract vehicles (Section 317 and VFC), and site-of-care economics
• Experience operating in lean or pre-commercial biotech environments, with a demonstrated track record of building market access capabilities from the ground up
• Proven ability to balance strategic thinking with hands-on execution
• Strong cross-functional leadership and stakeholder influence skills
• Experience managing gross-to-net financial modelling, including rebate strategy across payers
• Demonstrated ability to work collaboratively with HEOR teams to translate cost-effectiveness models, budget impact analyses, and payer value dossiers into P&T committee submissions or ICER reviews
• Prior engagement with CDC immunization programs, state immunization programs, or ACIP-adjacent policy processes; understanding of how ACIP recommendation language drives uptake across channels